Current Report Filing (8-k)

0000012208false00000122082023-01-102023-01-100000012208us-gaap:CommonClassAMember2023-01-102023-01-100000012208us-gaap:CommonClassBMember2023-01-102023-01-10

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report:   January 10, 2023

(Date of earliest event reported)

BIO-RAD LABORATORIES, INC.

(Exact name of registrant as specified in its charter)

Commission File Number: 1-7928

 

Delaware						94-1381833
(State or other jurisdiction of incorporation)						(I.R.S. Employer Identification No.)

 

1000 Alfred Nobel Dr.

Hercules, California 94547

(Address of principal executive offices, including zip code)

 

[phone]

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Class A Common Stock, Par Value $0.0001 per share

BIO

New York Stock Exchange

Class B Common Stock, Par Value $0.0001 per share

BIOb

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

			Emerging growth company			☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.						☐

---

ITEM 7.01    Regulation FD Disclosure.

As previously announced, Norman Schwartz, President and CEO of Bio-Rad Laboratories, Inc. (“Bio-Rad”), plans to present a company overview at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 4:30 p.m. Pacific Time. The presentation will be followed by a Q&A session with participation from Bio-Rad’s Executive Vice President and COO Andrew Last, and Executive Vice President and CFO Ilan Daskal. A link to a live webcast of the event will be accessible in the Investor Relations section of Bio-Rad’s website at bio-rad.com. A copy of the J.P. Morgan Healthcare Conference presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in Item 7.01 of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

ITEM 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

No.      Description

99.1 J.P. Morgan Healthcare Conference Presentation of Bio-Rad Laboratories, Inc. dated January 10, 2023

104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document

---

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  

BIO-RAD LABORATORIES, INC.

Date:

January 10, 2023

By:

/s/ Ilan Daskal

Ilan Daskal

Executive Vice President and Chief Financial Officer